PMP Inhibitor Screening With Patient-Derived Stable Cell Lines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy drugs are ineffective against pseudomyxoma peritonei (PMP), a rare cancer with poor vascularization that spreads easily within the peritoneal cavity, necessitating high-risk surgery without viable alternative treatments, and lacks a platform for pre-clinical drug testing.
Innovation Solution
Development of pseudomyxoma peritonei (PMP) inhibitors, such as myxomapeptin or its analogs, identified through high-throughput screening using stable cell lines derived from patient peritoneal tumor tissues, combined with metabolomics and cheminformatics tools, and validated by cell viability and mitochondrial stress assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chemotherapy drugs are used, then treatment of common cancers is effective, but treatment of pseudomyxoma peritonei is ineffective
Solution Approach 1:
The patent employs high-throughput screening to systematically test natural products against PMP cell lines, changing the screening parameters to specifically target rare cancers. This approach identifies compounds with optimized biological activity parameters for PMP, such as cytotoxicity against PMP cells while sparing normal cells, thereby resolving the contradiction between general chemotherapy effectiveness and specific applicability to rare cancers
Solution Approach 2:
The patent creates stable cell lines that replicate PMP tumor characteristics in vitro, serving as a model system to screen and identify effective compounds before clinical application. This copying approach allows pre-clinical testing to validate drug effectiveness specifically for PMP, addressing the lack of viable alternative treatments and enabling targeted drug discovery for this rare cancer
2Reliability
If high-risk intensive surgery is performed, then cancer removal is achieved, but patient safety is compromised
Solution Approach 1:
The patent implements pre-clinical drug testing using stable PMP cell lines to identify and validate effective therapeutic agents before surgical intervention. This preliminary action allows selection of patients who may respond to chemotherapy, potentially reducing or eliminating the need for high-risk intensive surgery in certain cases, thereby maintaining cancer removal efficacy while reducing surgical risks
Solution Approach 2:
The patent introduces pharmacological agents as intermediaries between the patient and surgical intervention. By identifying drugs that can effectively treat PMP through high-throughput screening and validation, the therapy serves as an intermediary option that may control or reduce tumor burden, potentially making surgery less intensive or avoiding it altogether, thus reducing harmful surgical factors while maintaining treatment efficacy
3Reliability
If natural products are screened, then bioactive compounds are identified, but novel chemistry is not targeted
Solution Approach 1:
The patent integrates multiple complementary approaches: high-throughput screening for bioactivity validation, metabolomics for chemical identification, and cheminformatics tools (GNPS, MZmine, SIRIUS) for structural analysis. This multi-functional platform simultaneously targets both known bioactive compounds and novel chemical structures, resolving the contradiction between reliable bioactivity identification and chemical diversity exploration by making the system versatile in handling both established and novel compounds
Data Source
AI summary
In general, disclosed herein are compositions and methods for treating pseudomyxoma peritonei (PMP). Compounds disclosed herein for treating pseudomyxoma peritonei may include PMP inhibitors of Formula I:or a pharmaceutically acceptable salt thereof.